Men’s cancer is a particularly deadly disease that affects women disproportionately.

That’s why there’s been an urgency to get men off drugs like Provenge, the first drug to treat breast and prostate cancer patients with a low-dose of the drug.

The drug is now available in Canada and the United States, and it can be used as a first line of defense against a range of cancers, including prostate, colon, lung, and esophageal cancers.

But it’s not yet available to women, and some doctors are concerned that it won’t be for years.

According to a study released Tuesday, the low-risk version of Provenge could be effective for treating up to 10 months of cancer.

The researchers found that it’s less likely to be toxic and can be taken for as little as one month, when the risk of death is only 1 per 100,000.

It’s not the first time scientists have tried to find a way to lower the risk for men, but there are a lot of other factors that need to be taken into account.

For example, the new drugs aren’t available in all countries, so there’s a risk of misclassification, said study lead researcher Dr. Andrew Schlechtman.

If a drug like Prostege is approved for use in women, the only way to know if it’s safe is to see if it works in a trial.

But because of the way that Provenge works, researchers have had to make some adjustments in their trials to make sure that they’re taking the risk into account when prescribing the drug, said Schleech.

The researchers have shown that they can lower the dose of Prosteger to just 1.5 milligrams of the protein that makes Provenge active.

That means the drug will be as effective as Provenge for a period of 10 months in men.

The study didn’t look at how the drug compares to other men’s drugs, which can have significantly different doses.

However, the researchers found no significant difference in side effects between Provenge and other men-focused drugs, like the anti-malarial and anti-cancer drugs, according to the study.

In addition to reducing the side effects of the anti-“malarial” drug, Schlechtman said, Prostegend could be a good option for men who want a less aggressive form of treatment.

In other words, a lower dose of the compound could make the most of a man’s existing immune system to fight off the cancer cells.

“Men’s cancer treatments should not be limited to those that treat a particular type of cancer,” he said.

The team plans to start its trials with men in the next few months, and to start using the drug in the United Kingdom in 2018.

Schlechtmann and his colleagues have now completed six years of research on Prostegenes, and they expect to continue to improve the drug by developing additional ingredients and analyzing how the compound works.

For now, the team is working on how the molecule works in the body, and Schleichton is hoping to be able to see a real clinical trial in about 10 months, Schachterman said.

“The next step will be to determine if the drug works better for men with other types of cancers as well,” he added.

But he cautioned that there’s still a lot to learn about the molecule, and not all men have the same types of tumors.

For example, women tend to have a higher incidence of cancers that target the endocrine system, he said, so researchers are interested in studying how the cancer-fighting properties of Progestin affect the endometrium.

“If we can understand the way in which the endocannabinoid system regulates our immune system, we can better understand how this drug works in men with cancer and what the benefits are,” Schachters said.

This story was provided by The Associated Press, which pays for news coverage.